A study has found fresh evidence that the diabetes drug rosiglitazone is associated with an increased risk of congestive heart failure, acute myocardial infarction and mortality.The retrospective study of 159,026 patients aged over 66 during a four year period showed rosiglitazone increased the risk of congestive heart failure by 60%, myocardial infarction by 40% and death by 29% compared with other oral hypoglycaemic agent combination therapies.It ...
Speak with a member of the team about providing Nursing Times for your whole team
Are you a student nurse? Take advantage of a discounted rate by clicking here (Graduation date required)
Already have an account? Sign in
EMAP Publishing Limited Company number
7880758 (England & Wales) Registered address:
7th Floor, Vantage London, Great West Road,
Brentford, United Kingdom, TW8 9AG